Pages that link to "Q33319315"
Jump to navigation
Jump to search
The following pages link to Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women (Q33319315):
Displaying 7 items.
- Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer (Q24293323) (← links)
- uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer (Q33376876) (← links)
- Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. (Q35872701) (← links)
- Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. (Q37415814) (← links)
- Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial (Q37712766) (← links)
- A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. (Q38288739) (← links)
- COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels (Q38701659) (← links)